Erasca proposes $500M common stock public offering

Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company, announced a proposed underwritten public offering of $500 million of shares of its common stock.

All shares to be sold in the proposed offering are being offered by Erasca. The company also intends to grant underwriters a 30-day option to purchase up to an additional $75 million of shares. Erasca noted there is no assurance as to whether or when the offering may be completed, or as to its actual size or terms.

The company said it intends to use net proceeds from the offering, along with existing cash, cash equivalents, and marketable securities, to fund research and development of its product candidates and other development programs, as well as for working capital and general corporate purposes.

J.P. Morgan, Morgan Stanley, Jefferies, and Evercore ISI are acting as joint book-running managers for the proposed offering.

The securities are being offered pursuant to a shelf registration statement on Form S-3 filed with the Securities and Exchange Commission on July 13, 2026, which automatically became effective upon filing.

You May Also Be Interested In

• Notice to Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Insulet Corporation (NASDAQ: PODD); Photronics, Inc. (NASDAQ: PLAB); and Via Transportation, Inc. (NYSE: VIA): Grabar Law Office is Inv
• First Choice Healthcare and Westin Acquisition plan $650M SPAC merger
• Dyne Therapeutics prices $375M public stock offering at $20.50